Abaloparatide injections (marketed as TYMLOS in the United State) is approved by the FDA for the treatment of osteoporosis who have had their menopause and are at high risk for bone fracture.
The study Sponsor has developed an investigational device (Abalo patch) which can be used to deliver abaloparatide via application through the skin. This is being developed as a potential alternative for daily subcutaneous injections as currently approved.
The purpose of the study is to see how effective, safe and tolerable the study drug patch device is compared with subcutaneous injections for treatment of osteoporosis in postmenopausal women.
Osteoporosis is a condition in which the bones become weak and brittle and is common in women who have had their menopause. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral (spine) fractures and increase bone mineral density in the lumbar spine, hips and thighs.
The Clinical Study will last approximately 1 year consisting of 17 clinic visits. All participating patients will receive actual treatment drug.